John Colwell to Male
This is a "connection" page, showing publications John Colwell has written about Male.
Connection Strength
0.182
-
Racial disparities in trends for cardiovascular disease and procedures among hospitalized diabetic patients. Ethn Dis. 2008; 18(2):131-5.
Score: 0.016
-
Diabetes-related lower extremity amputation rates fall significantly in South Carolina. South Med J. 2007 Aug; 100(8):787-90.
Score: 0.015
-
Aspirin therapy in diabetes. Diabetes Care. 2004 Jan; 27 Suppl 1:S72-3.
Score: 0.012
-
Treatment for the procoagulant state in type 2 diabetes. Endocrinol Metab Clin North Am. 2001 Dec; 30(4):1011-30.
Score: 0.010
-
Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care. 1998 Apr; 21(4):510-5.
Score: 0.008
-
Preventive care among people with diabetes in biracial population. J S C Med Assoc. 1997 Dec; 93(12):443-7.
Score: 0.008
-
Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. Diabetes. 1996 Jul; 45 Suppl 3:S87-90.
Score: 0.007
-
The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Ann Intern Med. 1996 Jan 01; 124(1 Pt 2):131-5.
Score: 0.007
-
Forum Two: Unanswered research questions about metabolic control in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996 Jan 01; 124(1 Pt 2):178-9.
Score: 0.007
-
Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes. Diabetes Care. 1995 Aug; 18(8):1150-5.
Score: 0.007
-
Platelet plasminogen activator inhibitor 1 in patients with type II diabetes. Diabetes Care. 1994 Aug; 17(8):818-23.
Score: 0.006
-
Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators. Diabetes Care. 1993 Jan; 16(1):37-44.
Score: 0.006
-
Hemostatic alterations with exercise conditioning in NIDDM. Diabetes Care. 1990 Feb; 13(2):87-92.
Score: 0.005
-
V.A. Cooperative Study of antiplatelet agents in diabetic patients after amputation for gangrene: unobserved, sudden, and unexpected deaths. J Diabet Complications. 1989 Oct-Dec; 3(4):191-7.
Score: 0.004
-
Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med. 2006 Sep-Oct; 4(5):427-32.
Score: 0.004
-
Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care. 1986 Mar-Apr; 9(2):140-8.
Score: 0.004
-
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis. Haemostasis. 1986; 16(6):433-8.
Score: 0.003
-
Diabetic lipoprotein deficient serum: its effect in low density lipoprotein (LDL) uptake and degradation by fibroblasts. Metabolism. 1985 Dec; 34(12):1079-85.
Score: 0.003
-
Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes. 1985 Nov; 34(11):1127-33.
Score: 0.003
-
Urinary kallikrein excretion in insulin-dependent diabetes mellitus and its relationship to glycemic control. J Clin Endocrinol Metab. 1984 Aug; 59(2):278-86.
Score: 0.003
-
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: I. Design, methods, and baseline characteristics. Control Clin Trials. 1984 Jun; 5(2):165-83.
Score: 0.003
-
Effect of metabolic control on lipid, lipoprotein, and apolipoprotein levels in 55 insulin-dependent diabetic patients. A longitudinal study. Diabetes. 1983 Jan; 32(1):20-5.
Score: 0.003
-
Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia. 1982 Jun; 22(6):430-6.
Score: 0.003
-
Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care. 2000 Oct; 23(10):1478-85.
Score: 0.002
-
Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care. 2000 Sep; 23(9):1316-20.
Score: 0.002
-
The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications. 1999 Sep-Dec; 13(5-6):307-13.
Score: 0.002
-
Platelet adhesion and aggregation in diabetes mellitus. Metabolism. 1979 Apr; 28(4 Suppl 1):394-400.
Score: 0.002
-
Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. Arch Intern Med. 1998 Dec 7-21; 158(22):2485-90.
Score: 0.002
-
Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care. 1998 Apr; 21(4):574-9.
Score: 0.002
-
Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with an without vascular disease. Metabolism. 1977 Mar; 26(3):279-85.
Score: 0.002
-
Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med. 1997 Jan 27; 157(2):181-8.
Score: 0.002
-
Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study. Diabetes Care. 1996 Dec; 19(12):1375-81.
Score: 0.002
-
Altered platelet function in diabetes mellitus. Diabetes. 1976; 25(2 SUPPL):826-31.
Score: 0.002
-
Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995 Aug; 18(8):1113-23.
Score: 0.002
-
Glycemic control and complications in type II diabetes. Design of a feasibility trial. VA CS Group (CSDM) Diabetes Care. 1992 Nov; 15(11):1560-71.
Score: 0.001
-
A new case of xanthinuria. Am J Med. 1972 Nov; 53(5):690-2.
Score: 0.001
-
Effect of resection of adipose tissue on the diabetes and hyperinsulinism of benign symmetric lipomatosis. Diabetes. 1972 Jan; 21(1):13-5.
Score: 0.001
-
Studies of insulin and growth hormone secretion in a subject with hepatoma and gypoglycemia. Diabetes. 1971 Sep; 20(9):607-14.
Score: 0.001
-
Inhibition of insulin secretion by catecholamines in pheochromocytoma. Ann Intern Med. 1969 Aug; 71(2):251-6.
Score: 0.001
-
Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes. 1988 Dec; 37(12):1652-7.
Score: 0.001
-
Diminished insulin response to hyperglycemia in prediabetes and diabetes. Diabetes. 1967 Aug; 16(8):560-5.
Score: 0.001
-
Glycosylation of low density lipoprotein in patients with type 1 (insulin-dependent) diabetes: correlations with other parameters of glycaemic control. Diabetologia. 1986 Oct; 29(10):685-9.
Score: 0.001
-
Predicting insulin requirements for a portable insulin pump using the Biostator. Evidence for reversible insulin resistance in poorly controlled type I diabetics. Diabetes. 1983 Oct; 32(10):908-14.
Score: 0.001
-
Effect of metabolic control with insulin on plasma von Willebrand factor activity (VIIIR:WF) in diabetes mellitus. Thromb Res. 1980 Jan 1-15; 17(1-2):261-6.
Score: 0.001
-
The effect of oral glucose on von Willebrand factor activity in normal and diabetic subjects. Clin Endocrinol (Oxf). 1977 Jun; 6(6):437-42.
Score: 0.000
-
Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation. Diabetes. 1972 Feb; 21(2):108-13.
Score: 0.000